Deciphera Pharmaceuticals, LLCWaltham, Massachusetts, United States
Disclosure information not submitted.
Paper 61 - INSIGHT: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF RIPRETINIB VS SUNITINIB IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR PREVIOUSLY TREATED WITH IMATINIB WITH KIT EXON 11+17/18 MUTATIONS
Saturday, November 4, 20239:00 AM – 10:00 AM